Biotech

All Articles

Ideaya bags possibility on Biocytogen bispecific ADC in $400M offer

.Ideaya Biosciences is wagering $400 thousand in biobucks that a bispecific antibody-drug conjugate ...

Takeda takes $140M loss on stopped working epilepsy medicine, promotes FDA manage

.We presently understand that Takeda is actually planning to locate a course to the FDA for epilepsy...

VBI Injections apply for insolvency, looks for possession purchase

.Immunology biotech VBI Vaccinations is actually veering hazardously close to the moment of truth, a...

Celldex anti-cKIT antitoxin decrease hives in an additional period 2 research study

.It is actually challenging to muscle in on an area as very competitive as immunology, but Celldex R...

Boehringer offers up to $1.3 B for gate inhibitor biotech

.Boehringer Ingelheim is actually offering up to $1.3 billion for Nerio Rehabs as well as a preclini...

Ventyx's last hope for inflammatory med ends in Crohn's failure

.Ventyx Biosciences' Crohn's condition medication carried out certainly not help patients attain rem...

Cognition's stage 2 SHINE information blemish Alzheimer's prospect

.Cognition Therapies' stage 2 SHINE trial has taken a few of the luster off the Alzheimer's illness ...

BMS axes bispecific months after filing to operate phase 3 trial

.Bristol Myers Squibb has had a whiplash change of heart on its BCMA bispecific T-cell engager, halt...

Charles Baum manages Terremoto as chief executive officer

.Charles Baum, M.D., Ph.D., that supervised Mirati Therapeutics' $ 5.8 billion sale to Bristol Myers...

Asarina to close after attempts to partner Tourette's drug fail

.After connecting to greater than 200 business to companion a Tourette disorder therapy that showed ...